BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 202,300 shares, an increase of 113.4% from the January 31st total of 94,800 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average trading volume of 373,300 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price objective on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

BriaCell Therapeutics Stock Performance

BCTX opened at $3.67 on Monday. The firm’s fifty day moving average is $5.77 and its two-hundred day moving average is $9.62. The firm has a market cap of $13.61 million, a PE ratio of -0.28 and a beta of 1.59. BriaCell Therapeutics has a twelve month low of $3.33 and a twelve month high of $52.93.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, December 16th. The company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.10). Equities analysts forecast that BriaCell Therapeutics will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On BriaCell Therapeutics

Several hedge funds have recently bought and sold shares of BCTX. Vontobel Holding Ltd. raised its holdings in shares of BriaCell Therapeutics by 37.5% during the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after acquiring an additional 30,000 shares during the period. Virtu Financial LLC acquired a new stake in shares of BriaCell Therapeutics during the fourth quarter worth $27,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of BriaCell Therapeutics during the fourth quarter worth $32,000. 15.42% of the stock is currently owned by institutional investors and hedge funds.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.